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Abstract
Autoimmunity results from a breakdown in tolerance mechanisms that regulate autoreactive
lymphocytes. We recently showed that during innate immune responses, secretion of IL-6 by
dendritic cells (DCs) maintained autoreactive B cells in an unresponsive state. In this study, we
describe that TLR4-activated DCs from lupus-prone mice are defective in repressing autoantibody
secretion, coincident with diminished IL-6 secretion. Reduced secretion of IL-6 by MRL/lpr DCs
reflected diminished synthesis and failure to sustain IL-6 mRNA production. This occurred
coincident with lack of NF-κB and AP-1 DNA binding and failure to sustain IκBα
phosphorylation. Analysis of individual mice showed that some animals partially repressed Ig
secretion despite reduced levels of IL-6. This suggests that in addition to IL-6, DCs secrete other
soluble factor(s) that regulate autoreactive B cells. Collectively, the data show that MRL/lpr mice
are defective in DC/IL-6-mediated tolerance, but that some individuals maintain the ability to
repress autoantibody secretion by an alternative mechanism. The Journal of Immunology, 2007,
178: 4803–4810.
Systemic lupus erythematosus (SLE)4 is a multiorgan autoimmune disease characterized by
the production of autoantibodies to nuclear components. Alternating periods of flares and
remissions are associated with an increased burden of apoptotic cells, the formation of
immune complexes, and inflammation (1). The etiology of SLE remains unknown; however,
multiple immunoregulatory defects have been identified in lupus-prone mice (2–13),
including complement deficiencies, TCR signal transduction anomalies, and dysfunctional
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cytokine secretion by macrophages (Mφs). These defects contribute to the onset and/or
pathogenesis of SLE, while a breakdown in tolerance leads to the formation of
autoantibodies and immune complexes that may play a role in vasculitis, glomerulonephritis,
and cerebritis (14).
Studies in Ig transgenic (Tg) mouse models have defined anergy as a state of
unresponsiveness that regulates autoreactive B cells in the periphery (15–19). Anergic B
cells fail to secrete Ab in response to LPS or Ag immunization due to receptor
unresponsiveness (17, 18, 20). Some anergic B cells exhibit reduced surface IgM levels (21,
22), decreased lifespan (20, 23), and exclusion from the lymphoid follicle (23, 24). In the
case of B cells specific for the lupus-associated Ag, Smith (Sm), a partially anergic
phenotype is evident. Sm-specific B cells from 2-12H/Vκ8 Ig Tg mice are unable to secrete
Ig in response to LPS, yet maintain surface IgM levels, exhibit a normal lifespan, and
remain competent to enter the B cell follicle (18). Recently, we described that Sm-specific B
cells purified from myeloid dendritic cells (myDCs) and Mφs regain the ability to secrete Ig
in response to LPS (25). The data show that secretion of IL-6 by DC/Mφs represses LPS-
induced Ig secretion by autoreactive B cells without repressing acutely stimulated naive B
cells. This mechanism of tolerance is not limited to Sm-specific B cells as chronically Ag-
experienced HEL- and Ars/A1-specific B cells are similarly affected (25). These findings
identify a unique mechanism of B cell tolerance wherein DCs and Mφs play a central role in
regulating autoimmunity during innate immune responses.
myDCs and plasmacytoid DCs have been described as positive regulators of immunity
promoting growth and differentiation of some B cells through the secretion of IL-12, IL-6,
BLyS, and APRIL (26–28). Specifically, IL-6 was found to promote plasma cell survival
(29, 30). Although this seems paradoxical, the data indicate that IL-6 differentially regulates
naive and chronically Ag-experienced B cells (25). Studies identifying IL-6 as a positive
regulator focused on B cells from non-Tg mice where the proportion of autoreactive cells is
low. In contrast, the studies showing that IL-6 represses autoantibody production used self-
reactive Ig Tg models where the B cells were constantly exposed to self-Ag (25). Thus, IL-6
acts as a positive or negative regulator of B cells depending on the history of BCR ligation.
We propose that chronic BCR ligation by self-Ag reprograms IL-6R-mediated outcomes
allowing naive B cells to produce Ig in response to polyclonal stimulation while
simultaneously repressing autoreactive B cells from producing autoantibody. These findings
identify a novel B cell tolerance mechanism, and suggest that overcoming tolerance in SLE
might be associated with defects in the repression of autoreactive B cells by myDCs and/or
Mφs.
In this report, we show that LPS-activated DCs from MRL/lpr mice inefficiently repress
Sm-specific Ig secretion, coincident with diminished IL-6 secretion. Mechanistically,
diminished secretion of IL-6 resulted from decreased synthesis of IL-6 mRNA coincident
with decreased IκBα phosphorylation and reduced DNA binding by NF-κB and AP-1.
These data identify signal transduction defects in DCs that occur coincident with diminished
IL-6 secretion and failure to repress Ig secretion by autoreactive B cells. Further analysis of
DC-mediated tolerance mechanisms revealed that DC conditioned medium (CM) from some
MRL/lpr mice repressed Ig secretion despite low levels of IL-6. This suggested that
additional soluble factors are involved in repressing autoantibody secretion. These findings
implicate DC defects in the breakdown of tolerance in lupus-prone mice and suggest that
defects in multiple factors may be required for the complete breakdown of tolerance
associated with autoimmunity.
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2-12H/Vκ8/Cκ−/− Ig transgenic mice were previously described (18, 25). MRL/MpJ-Faslpr/J
(MRL/lpr) and C57BL/6J (B6) mice were purchased from The Jackson Laboratory, and
NZM2410 mice from Taconic Farms. NZBxNZWF1 mice were obtained from Trine
Jorgensen (University of Colorado), MRL/MpJ (MRL) and B6.Faslpr (B6.lpr) from Stephen
Clarke (University of North Carolina). 2-12H/Vκ8/Cκ−/− mice were used at 9 to 17 wk of
age. All other mice were used at 6- to 10 wk old. All studies were approved by the
Institutional Animal Care and Use Committee.
Reagents and antibodies
7-Aminoactinomycin D (7-AAD), rIL-6, and Abs to CD11c, CD11b, B220, and IL-6 were
purchased from BD Biosciences, GR1 and TLR4 from eBio-sciences, phospho-IκBα from
Cell Signaling, IκBα and β-tubulin from Santa Cruz Biotechnology, and IgG HRP from
Promega. Streptavidin-alkaline phosphatase (AP) was purchased from Southern Biotech,
anti-actin, TEPC 183, and Escherichia coli 055:B5 LPS from Sigma-Aldrich, 5,6-
dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) from Calbiochem, E. coli 0111:B4 LPS
from List Biological Laboratories, mouse GM-CSF and IL-4 from PeproTech, poly(I:C) and
R848 from InvivoGen, and CpG oligodeoxynucleotides (ODN) and non-CpG ODN from
Coley Pharmaceutical Group. JA12.5, 54.1, 187.1, HB100, and CRL 1969 were purified
from hybridoma culture supernatant.
Cell purification
B cells were purified from 2-12H/Vκ8/Cκ−/− spleens by negative selection (StemCell
Technologies) (25). Biotinylated CD3 Ab was added to the Ab mixture to increase the
efficiency of T cell depletion. B cells were 86–93% pure with <3% T cells and <7% DCs/
Mφs. Splenic CD11c+ cells (~70% pure) were purified by positive selection (Miltenyi
Biotech) and found to contain 20% lymphocytes and 10% Mφs.
Bone marrow-derived DC cultures
Bone marrow-derived DCs (BMDC) were generated as previously described (25). BMDCs
were >95% CD11c+ (CRL 1969 hybridoma). CM was made from 1 × 104 BMDCs (0.2 ml)
cultured for an additional 4 days with or without Sigma LPS (30 μg/ml). 5 × 105 BMDCs
(0.2 ml) were cultured for an additional 4 days with or without poly(I:C) (50 μg/ml), R848
(10 μg/ml), CpG ODN (1 μg/ml), or non-CpG ODN (1 μg/ml). In experiments where RNA
was isolated or nuclear extracts were prepared, BMDCs were stimulated with E. coli
0111:B4 LPS (List Biological Laboratories) that was re-purified (31) and confirmed to be
unable to induce IL-6 secretion by TLR4−/− DCs.
B cell cultures
Splenocytes containing 1 × 105 B cells, or the equivalent number of purified B cells, were
cultured with Sigma LPS (30 μg/ml) for 4 days. In the mixed B cell experiments, purified
B6 (5 × 104; IgMb) and 2-12H/Vκ8 (5 × 104; IgMa) B cells were cocultured with LPS for 4
days as above. BMDCs, CD11c+ splenocytes, or BMDC CM (25% of final volume) were
added to B cell cultures on day 0. The IL-6 in DC CM was neutralized with either anti-IL-6
Ab or a control rat IgG1 Ab (54.1).
ELISA
IgMa/κ (encoded by 2-12H/Vκ8/Cκ−/−) was captured with anti-κ (187.1), detected with
biotinylated anti-IgMa (HB100) and streptavidin-AP as previously described (18). Purified
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mouse IgMa/κ (TEPC 183) served as the standard control. IgMa/κ levels were plotted as
“percentage of control” defined by the level of Ig secretion in LPS-stimulated cultures of
purified 2-12H/Vκ8/Cκ−/− B cells (100%). IL-6 was quantitated by capturing with anti-IL-6
(clone MP5-20F3) and detecting with biotinylated anti-IL-6 (clone MP5-32C11) and
streptavidin-AP. rIL-6 served as the standard control.
Real-time RT-PCR
RNA was prepared from BMDCs treated with re-purified LPS (15 μg/ml) by solubilization
in Trizol (Invitrogen Life Technologies) and treatment with Turbo DNase (Ambion).
Reverse transcription with oligo(dT) primers was performed with Superscript II (Invitrogen
Life Technologies). The amount of IL-6 message was determined using the TaqMan Assay-
On-Demand primer-probe sets (Applied Biosystems) and the ABI 7000 sequence detection
system. IL-6 mRNA transcript levels were normalized to the amount of 18S ribosomal RNA
transcription according to the following equation: %18S = 2^ [-(IL-6 – 18S units)]. To
measure IL-6 mRNA stability, BMDCs were stimulated with re-purified LPS (15 μg/ml) for
6 h and then treated with 50 μM DRB for 15, 30, and 60 min to block transcription. mRNA
was quantitated by RT-PCR as described above.
EMSA
BMDCs were stimulated with re-purified LPS (15 μg/ml) and gel shift assays were
performed as previously described (32).
Statistical analysis
Exact Wilcoxon rank sum test was used for most unpaired two-sample comparisons. When
total sample size was small (<8), t test was used instead. For test differences between paired
observations, exact Wilcoxon signed rank test was used. Values of p < 0.05 were considered
significant and denoted by an asterisk (*).
Results
The frequencies of splenic myDCs and Mφs are not diminished in MRL/lpr mice
Maintaining B cell tolerance during activation of the innate immune system is crucial in
preventing autoimmunity. We have previously shown that stimulation through TLR4
activates myDCs and Mφs to secrete soluble factors thereby repressing Ig secretion by
chronically Ag-experienced (autoreactive) B cells (25). To determine whether the
breakdown of tolerance in lupus-prone mice was associated with the lack of a repressive cell
type, we compared the frequency of splenic Mφ and DC subsets in MRL/lpr and B6 mice.
As shown in Fig. 1 and Table I, the frequencies of myDCs (CD11chigh/CD11bint/high) and
plasmacytoid DCs (pDCs, CD11clow/CD11b−/B220+/GR1+) were not significantly different.
The lymphoid DCs (lyDCs, CD11clow/CD11b−/B220−/GR1−) were significantly decreased
in MRL/lpr; however, this population is not involved in DC/Mφ-mediated tolerance (25).
The CD11c−/CD11bhigh and CD11c−/CD11blow populations were increased in MRL/lpr
mice, raising the possibility that these populations might secrete an activator that enhances
Ig secretion. However, when isolated by cell sorting, these populations did not augment
LPS-induced Ig secretion or affect the ability of B6 DCs to regulate Ig secretion by Sm-
specific B cells (data not shown), suggesting that neither population promotes the loss of B
cell tolerance. Thus, neither diminished frequency of myDCs and Mφs nor secretion of an
activator accounts for the loss of tolerance in MRL/lpr mice.
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DCs from MRL/lpr mice fail to efficiently repress Sm-specific B cells
LPS-activated DCs from B6 mice regulate chronically Ag-experienced B cells (25). To
assess whether DCs from MRL/lpr mice were capable of repressing Ig secretion, we
cocultured Sm-specific B cells with BMDCs from B6 or MRL/lpr mice (Fig. 2A). Compared
with B6 DCs, MRL/lpr DCs were less efficient at repressing Sm-specific B cells when
cultured at B cell: DC ratios of 10:1, 20:1, and 100:1 (p = 0.016, 0.004, and 0.015,
respectively). These differences were not due to contaminating cells, because BMDCs from
B6 and MRL/lpr mice contained >95% myDCs, and sorted B cells compared with
negatively selected B cells from 2-12H/Vκ8 mice cultured with DCs from MRL/lpr mice
exhibited similar results (data not shown). To determine whether splenic DCs were also
defective in repressing autoreactive B cells, splenic CD11c+ cells were isolated from B6 and
MRL/lpr mice, and cocultured with B cells from 2-12H/Vκ8 mice (B cell: DC ratio 10:1).
As shown in Fig. 2B, ex vivo B6 DCs repressed significantly better than DCs purified from
MRL/lpr mice (p = 0.015), indicating that the defect was not specific to BMDCs.
Collectively, the data indicate that myDCs from MRL/lpr mice are present at a normal
frequency, but they are defective in repressing Ig secretion by autoreactive B cells.
DCs from MRL/lpr mice are defective in IL-6 secretion
We previously showed that IL-6 secreted by DCs repressed autoreactive B cells (25). To
determine whether diminished IL-6 was associated with the inability of MRL/lpr DCs to
repress Sm-specific Ig secretion, we measured IL-6 secretion. LPS-activated BMDCs (Fig.
3A) and splenic CD11c+ cells (Fig. 3B) from MRL/lpr mice secreted significantly less IL-6
compared with B6 controls (p < 0.001 and p = 0.003, respectively). To assess whether this
defect was unique to MRL/lpr mice, we quantitated LPS-induced IL-6 secretion from
BMDCs from several other lupus-prone models. As shown in Fig. 3A, BMDCs from MRL,
NZM2410, and NZBxNZW F1 were defective in secreting IL-6 when compared with B6 (p
< 0.0001, p < 0.0001, and p = 0.002, respectively). Interestingly, B6.lpr mice were not
defective in secreting IL-6 (p = 0.932), suggesting that the inability to secrete IL-6 is
associated with the MRL background. Defective IL-6 production was not secondary to IL-10
inhibiting TLR signaling, as MRL/lpr DCs secreted decreased levels of IL-10 and
neutralizing IL-10 did not restore IL-6 levels (data not shown). To determine whether
defective IL-6 secretion was limited to stimulation through TLR4, we measured IL-6
secretion from MRL/lpr-derived DCs in response to other TLR ligands. As shown in Fig. 3,
C–E, IL-6 secretion was increased when MRL/lpr BMDCs were stimulated through TLR3
(poly(I:C), p = 0.006); however, secretion was defective when stimulated through TLR7
(R848, p = 0.028) and TLR9 (CpG ODN, p = 0.016). This indicates that not all TLRs are
affected by this defect and that mutation within the IL-6 structural gene is unlikely to
explain the reduced levels of IL-6. Collectively, the data indicate that DCs from multiple
strains of autoimmune mice exhibit defects in cytokine secretion induced through some
TLRs.
Diminished IL-6 secretion is not due to decreased TLR4 expression or survival
Expression of TLRs ensures that DCs are activated during innate immune responses. It was
possible that the decreased secretion of IL-6 from MRL/lpr DCs reflected a reduced
expression of surface TLR4. As shown in Fig. 4A, the expression of TLR4 on myDCs from
B6 (MFI 58.9 ± 12.6) and MRL/lpr (MFI 68.1 ± 10.9) mice was not significantly different.
Likewise, BMDCs from B6 and MRL/lpr mice did not differ in TLR4 expression (data not
shown), nor did they differ in viability as determined by 7-AAD staining at day 4 (Fig. 4B).
Thus, diminished surface expression of TLR4 or decreased survival do not account for the
decreased IL-6 secretion by LPS-activated DCs from MRL/lpr mice.
Gilbert et al. Page 5













Defective IL-6 secretion is associated with failure to sustain IL-6 transcription
Transcriptional regulation of IL-6 depends on several signal transduction pathways that
activate multiple transcriptional regulators including NF-κB and AP-1. To determine
whether the diminished secretion of IL-6 by MRL/lpr DCs was due to defective
transcriptional regulation, we LPS-stimulated BMDCs from B6 and MRL/lpr mice and
quantitated IL-6 mRNA levels by real-time PCR. The basal level of IL-6 mRNA in the
MRL/lpr mice was slightly lower than in B6 mice (Fig. 5A). Upon stimulation with LPS,
IL-6 mRNA levels in B6 and MRL/lpr DCs were dramatically increased; however, the
magnitude of the response by MRL/lpr BMDCs was 7-fold lower. Further, the sustained
levels of IL-6 mRNA production were higher in B6 compared with MRL/lpr mice (24 h and
96 h time points). To determine whether decreased mRNA stability contributed to the
decreased production of IL-6 message, BMDCs were LPS-stimulated for 6 h followed by
pharmacological attenuation of transcription. The levels of IL-6 mRNA in BMDCs from B6
and MRL/lpr mice were quantitated by RT-PCR. As shown in Fig. 5B, the rates of mRNA
degradation in the MRL/lpr DCs did not change over time; however, the IL-6 mRNA levels
in B6 DCs were reduced by 3-fold within 15 min of attenuating new transcription. This
indicates that IL-6 message is inherently unstable and that sustained production of IL-6
mRNA requires continual synthesis. Further, given that degradation was not observed in
DCs from MRL/lpr mice, the data indicate that increased degradation does not contribute to
the diminished IL-6 mRNA levels. This suggests that MRL/lpr DCs harbor a defect at or
upstream of transcriptional initiation that reduces the level of IL-6 mRNA and protein.
To assess whether decreased IL-6 mRNA levels were associated with defects in NF-κB or
AP-1 activation, we compared the DNA binding activity in nuclear extracts prepared from
B6 and MRL/lpr DCs. The DNA binding activity of NF-κB from LPS-stimulated B6 DCs
occurred within 10 min, with robust binding at 6 h. In contrast, the DNA binding activity of
NF-κB from MRL/lpr DCs was diminished at these same time points (Fig. 6A). This was
not a reflection of unequal protein loading, as the levels of an unrelated nuclear protein
(PCNA) were comparable. The specificity of NF-κB for the DNA probe was confirmed by
diminished complex formation in the presence of unlabeled probe (competitor DNA), and
failure of a mutant competitor DNA (mutant DNA) to reduce complex formation (Fig. 6B).
To identify the NF-κB subunits involved in DNA binding, we supershifted the DNA/protein
complex with subunit-specific Abs. As shown in Fig. 6C, p65 and c-Rel, but not p50, were
identified as components of the NF-κB complex formed in B6 DCs following 6 h LPS
stimulation. p65 and c-Rel anti-sera were specific for these components as preim-mune
serum failed to supershift a protein/DNA complex (data not shown). Similar to NF-κB,
DNA binding by AP-1 was also markedly diminished in DCs from MRL/lpr compared with
B6 mice (Fig. 6D). Thus, LPS-stimulated MRL/lpr DCs fail to activate key transcriptional
regulators required for IL-6 gene transcription.
Nuclear translocation of NF-κB is dependent on phosphorylation and degradation of IκB
(33). To assess whether the lack of NF-κB DNA binding was associated with defects in IκB
phosphorylation/degradation, we immunoblotted whole cell lysates from LPS-stimulated B6
and MRL/lpr BMDCs. B6 DCs showed induced phosphorylation of IκBα at 5 min that was
sustained through 6 h (Fig. 7A, left panel). In contrast, MRL/lpr DCs induced IκBα
phosphorylation at 5 min with maximal phosphorylation at 15 min. Phosphorylation was not
evident at 45 min or 6 h (Fig. 7A, right panel). Similarly, IκBα degradation was delayed
following LPS stimulation of MRL/lpr DCs, indicating that defects in TLR4-induced signal
transduction correlate with lack of IL-6 mRNA production and protein secretion. To assess
whether other TLR pathways in MRL/lpr DCs were similarly affected, we assessed IκBα
phosphorylation in response to TLR3 ligation. We showed in Fig. 3 that despite defects in
TLR4-, TLR7-, and TLR9-induced IL-6 production, TLR3-induced IL-6 production was
enhanced. This revealed that the defect in IL-6 production by MRL/lpr DCs did not affect all
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TLRs. To correlate TLR-induced protein secretion with TLR-mediated signal transduction,
we assessed IκBα phosphorylation in response to poly(I:C). As shown in Fig. 7B, poly(I:C)-
induced IκBα phosphorylation was comparable between DCs derived from B6 and MRL/lpr
mice. Collectively, the data suggest failure to sustain IκBα phosphorylation reduces NF-κB
activation, diminishes IL-6 transcription, and ultimately decreases IL-6 protein synthesis by
MRL/lpr DCs. This supports the idea that continuous TLR4 signal transduction is required
to maintain IL-6 secretion and suggests this is defective in DCs from lupus-prone mice (34).
Autoantibody secretion is repressed by IL-6 and other soluble factors
We have previously shown that IL-6 repressed 75% of Ig secretion by Sm-specific B cells
(25). In this study, we show that DCs from lupus-prone MRL/lpr mice exhibit markedly
decreased IL-6 levels coincident with their inability to regulate Ig secretion. To determine
the importance of decreased IL-6 in the breakdown of tolerance, we assessed the ability of
CM from B6 and MRL/lpr DCs to repress Ig secretion. CM allowed us to distinguish the
effects of soluble mediators from the effects of cell contact. As shown in Fig. 8A, DC CM
from most B6 mice repressed 70–90% of Ig secretion. In contrast, the ability of DC CM
from individual MRL/lpr mice to repress Ig secretion was extremely variable (10–90%
repression, p = 0.004). Given the central role for IL-6 in repressing autoantibody secretion
(25), we reasoned that if IL-6 were the sole repressive factor, there would be a direct
correlation between IL-6 in DC CM and Ig secretion. However, this broad range of
repression only partially correlated with IL-6 levels (data not shown). Despite the fact that
all MRL/lpr mice exhibited low levels of IL-6, four individuals still repressed 80–90% of Ig
secretion (Fig. 8A). To assess whether the low levels of IL-6 secreted by MRL/lpr mice
contributed to Ig repression, we neutralized any remaining IL-6 in the DC CM of mice
retaining repressive function, then assessed the ability of the CM to regulate Ig secretion. As
shown in Fig. 8B, neutralization partially restored Ig secretion (p = 0.031), confirming that
the low levels of IL-6 regulated Ig secretion. Interestingly, secretion comparable to controls
(100%) was never attained, suggesting that in addition to IL-6, other DC-derived soluble
mediators regulate Ig secretion. It was possible that the variability in repression by MRL/lpr
DC CM was due to the secretion of an activating factor by the MRL/lpr DCs. We addressed
this in two ways. First, we added rIL-6 to the MRL/lpr DC CM, and then assessed Ig
secretion by Sm-specific B cells. When added to the CM from three individual mice, rIL-6
repressed Ig secretion indicating that if activating factors were present, they did not override
the repressive effect of IL-6 (data not shown). In a second experiment, we assessed whether
MRL/lpr DCs secreted an activator by determining whether MRL/lpr DC CM activated
naive B6 B cells. We previously showed that DC CM did not repress naive B cells (25);
thus, the presence of an activator may be more evident when Ig secretion is not
simultaneously being repressed by the low levels of IL-6 in the MRL/lpr DC CM. The data
indicate that MRL/lpr DC CM did not increase Ig secretion of naive B6 B cells, indicating
that the dysregulated production of an activator is unlikely (data not shown).
Collectively, the data indicate that during innate immune responses, IL-6 and another
repressive factor(s) regulates B cells chronically exposed to Ag. Further, this mechanism
appears defective in lupus-prone mice coincident with diminished secretion of IL-6.
However, it remained unclear whether soluble factors secreted by LPS-activated DCs
repressed autoreactive B cells when present in mixed populations with naive cells. To assess
this, we cocultured naive (B6) and autoreactive (2-12H/Vκ8) B cells with DC CM prepared
from B6 and MRL/lpr DCs. As shown in Fig. 8C, DC CM prepared from B6 cells, but not
MRL/lpr cells, repressed Ig secretion in the mixed B cell cultures (p = 0.009) (Fig. 8C). The
data suggest that DC-mediated repression regulates mixed populations of autoreactive and
naive B cells.
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The defects leading to the breakdown in B cell tolerance remain a central focus in
understanding SLE. Previous studies showed that during innate immunity Sm-specific B
cells were regulated by myDCs and Mφs through the secretion of soluble mediators (25).
We propose a model where polyclonal activators stimulate myDCs and Mφs to secrete IL-6,
which selectively represses autoreactive B cells, while naive B cells mount a polyclonal Ab
response to bac-terial and viral Ags. In this report, we show that DCs from lupus-prone mice
are less efficient at repressing autoreactive B cells coincident with a defect in secreting IL-6.
This DC defect was not due to decreased survival or TLR4 expression, lack of a regulatory
DC subpopulation, or the secretion of factors that enhance Ig secretion. Instead, the reduced
IL-6 secretion resulted from the inability of MRL/lpr DCs to induce or maintain IL-6
transcription in response to LPS. Analysis of upstream signaling effectors showed that,
although LPS induced IκBα phosphorylation, it was not sustained. Further, DNA binding by
NF-κB and AP-1 were markedly decreased. These findings indicate that MRL/lpr DCs
exhibit a TLR4 signal transduction defect at, or upstream of, IκB kinase (IKK)/IκB/NF-κB
activation that results in diminished IL-6 mRNA production and protein secretion.
Previous data showed that rIL-6 effectively regulated chronically Ag-experienced B cells
(25). At several B cell: DC ratios, MRL/lpr DCs were less efficient at repressing Ig secretion
compared with B6 DCs. However, despite significant defects in IL-6 secretion, they still
repressed 53% of anti-Sm secretion at a ratio of 100:1 (Fig. 2A). Further, DC CM was less
efficient at repressing Ig secretion compared with intact DCs indicating that a contact-
dependent mechanism might partially regulate Ig secretion. In support of this, we have
observed that DCs deficient in TLR4 partially repressed LPS-induced Ig secretion; however,
repression was lost when the cells were separated in a Transwell apparatus (M. A. Kilmon
and B. J. Vilen, unpublished observations).
The finding that repression of Ig secretion by DCs is multifaceted fits well with the
heterogeneity of human disease. We propose that defects in any regulatory component may
predispose to autoimmunity, but complete loss of tolerance requires multiple defects. Our
data show that the repressive ability of LPS-activated MRL/lpr DCs was variable. Some
DCs efficiently repressed Ig secretion, despite diminished IL-6 production (Figs. 2, 3, A and
B, and 8A), while others failed to repress secretion coincident with reduced IL-6 levels.
Compared with the contact-dependent mechanism described above, this repressive activity
was apparent in the CM from some MRL/lpr mice, indicating that DCs secrete additional
repressive factors that contribute to the regulation of Ig secretion. Thus, despite markedly
decreased IL-6 secretion by DCs from all mice analyzed, some likely harbor defects in
another repressive factor(s) making them more susceptible to autoimmunity during innate
stimulation. Although a direct correlation between Ig secretion and IL-6 levels in MRL/lpr
mice was not evident, we favor the interpretation that IL-6 and another repressive factor
regulates Ig secretion because IL-6-deficient DCs repress LPS-induced Ig secretion
(unpublished observations) and neutralizing IL-6 only partially restored Ig secretion (Fig.
8B). This indicates that the low levels of IL-6 secreted by MRL/lpr DCs partially represses
Ig secretion, but that IL-6 is not the sole means of regulating autoimmunity during innate
immune responses.
The inability of LPS-stimulated MRL/lpr DCs to produce IL-6 and efficiently repress Ig
secretion suggests that defects in innate immune responses contribute to autoimmunity. Our
data show that DCs derived from MRL/lpr mice are unable to sustain IκB phosphorylation,
thereby reducing NF-κB DNA binding and IL-6 mRNA synthesis. This suggests an intrinsic
defect where lack of sustained TLR-mediated signal transduction leads to decreased IL-6
protein secretion. This could reflect a defect in the TLR signaling pathway or possibly the
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selective formation of NF-κB complexes that are less transcriptionally active. Aberrant
cytokine production and abnormal NF-κB activity in T cells and Mφs from lupus-prone
mice and lupus patients have been associated with decreased p65, increased p50
homodimers which are more inhibtory to gene transcription, reduced binding of p50/c-Rel
and p65 NF-κB complexes, and increased activity of histone deacetylases (35, 36).
Unfortunately we could not identify the NF-κB subunits formed by MRL/lpr DCs because
DNA binding was not observed at levels sufficient for supershifting.
MyD88-dependent, TLR-induced activation of NF-κB and AP-1 is mediated through
TRAF6 (37). Thus, the findings that both NF-κB and AP-1 DNA binding activity are
reduced (Fig. 6), and that IL-6 secretion and IκBα phosphorylation are defective only upon
stimulation through MyD88-dependent TLRs (TLR4, 7, and 9, but not TLR3), suggest a
defect in the MyD88-dependent signaling pathway possibly at or upstream of TRAF6.
Alternatively, a defect at the level of the TLR4 receptor may occur. Yang et al. (34) showed
that persistent TLR4 signals are required for normal DC secretion of IL-6. In the case of
dysfunctional MRL/lpr DCs, the TLR4 receptor may become desensitized to LPS following
an initial stimulus, mimicking LPS removal and causing the decreased phospho-IκBα and
IL-6 mRNA levels seen at later time points (Figs. 5 and 7). In addition, exposure to
apoptotic cells may affect the TLR4 response. Apoptotic cells fail to induce inflammatory
responses, in part by repressing DC activation (38). Thus, the increased burden of apoptotic
cells associated with SLE may dysregulate some of the TLRs, rendering them incapable of
secreting cytokines that are needed to repress autoantibody secretion. In support of this,
others have shown that apoptotic cells cause defective IL-6 secretion by macrophages (10),
and mice functionally deficient in the phagocytosis of apoptotic cells get a lupus-like disease
(11).
Increased production of proinflammatory cytokines such as IL-6, contribute to the
inflammatory response and pathogenesis of lupus nephritis (39, 40). SLE patients (41–44)
and diseased lupus-prone mice (45–47) exhibit elevated serum IL-6 levels (2–19 pg/ml) but
fail to repress Ig secretion. Although elevated, this level of systemic IL-6 is insufficient to
repress autoreactive B cells in vitro (25). Therefore, we propose that colocalization of DCs
and B cells is necessary to provide sufficient IL-6 to repress Ig secretion. Our findings
showed that DCs derived from MRL/lpr mice secrete reduced levels of IL-6, coincident with
lack of Ig repression. We propose that once tolerance is overcome, autoantibody secretion
and immune complex formation induce systemic production of proinflammatory mediators,
promoting inflammation and pathogenesis. Consistent with this model, CpG-stimulated DCs
from SLE patients produced lower levels of IL-6 (48), whereas endothelial cells (49–51),
mesangial cells in the kidney (52, 53), and infiltrating monocytes/macrophages (54) secrete
elevated levels of IL-6. This suggests that IL-6 plays a beneficial role when released in a
local microenvironment between myDCs and autoreactive B cells, but when elevated
systemically, it induces inflammation, tissue destruction, and spontaneous Ig production by
activated B cells (41, 55–57). Therapies aimed at neutralizing the inflammatory effects of
IL-6 may have short-term benefits in treating lupus nephritis; however, they are likely to
promote loss of tolerance in newly emerging B cells during innate immune activation.
Ig secretion by B cells is induced by ligation of the TLR and/or BCR. BCR-induced Ig
secretion is regulated by lack of T cell help and sustained BCR-induced calcium signaling
and prolonged Erk activation (20, 58–60). In contrast, TLR-induced Ig secretion is regulated
by soluble factors secreted from DCs and Mφs (25). Although the mechanisms regulating
the BCR and TLR are unique, signals derived from chronic BCR stimulation impact TLR-
induced activation. For example, the chronic Erk activation associated with continuous
exposure to self-Ags represses TLR9-induced Ig secretion, whereas, acute Erk activation
following BCR stimulation of naive B cells promotes TLR9-induced Ig secretion (61, 62).
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Similarly, chronic BCR exposure to self-Ag reprograms IL-6R signal transduction to repress
Ig secretion (25). However, B cells that have been acutely stimulated and exposed to IFN-
αβ induce Ig secretion in response to IL-6 (27). Our data expand our understanding of IL-6
to include a role in repressing Ig secretion by autoreactive B cells. During autoimmunity, the
tolerance mechanisms that regulate autoreactive B cells become dysregulated. For many B
cells with autoreactive specificities, it remains unclear whether BCR and/or TLR responses
facilitate autoantibody production. Our studies of TLR-mediated responses in Sm-, HEL-,
and Ars/A1-specific autoreactive B cells identify DCs and Mφs as key regulatory cells
during innate immune responses, and show that DC-mediated tolerance is defective in lupus-
prone MRL/lpr mice. These findings implicate dysregulated innate immune responses in the
autoantibody production associated with SLE.
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The distribution of splenic myDCs and Mφs are comparable between B6 and MRL/lpr mice.
DC and Mφ subsets were separated based on CD11c and CD11b expression. Dot plots are
representative of nine mice each.
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DCs from MRL/lpr mice fail to efficiently repress Sm-specific Ig secretion. LPS-stimulated
(30 μg/ml) splenocytes (1 × 105 B cells) or purified B cells (1 × 105) were cocultured with
the indicated ratios of BMDCs (A), or ex vivo splenic DCs (B). Secreted IgMa/κ levels were
quantitated by ELISA from the day 4 culture supernatant. LPS-stimulated purified B cells
(100%) secreted 1–10 μg/ml IgMa/κ. Data represent 14 (A) and 8 (B) MRL/lpr mice. (▲,
Controls; ● B6, MRL/lpr).
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DCs from MRL/lpr mice are defective in IL-6 secretion upon TLR4, 7, and 9 stimulation,
but not upon TLR3 stimulation. 1 × 104 BMDCs (A) or 1 × 105 ex vivo splenic DCs (B)
were stimulated with LPS (30 μg/ml). 5 × 105 BMDCs were stimulated with poly(I:C) (50
μg/ml) (C), R848 (10 μg/ml) (D), and non-CpG ODN (●/□) or CpG ODN (●/○) (1 μg/ml)
(E). IL-6 was quantitated by ELISA from the day 4 culture supernatants. Data represent at
least 5 mice per group. (●, B6; ○, MRL/lpr; ▲, MRL; △, B6.lpr; ◆, NZM2410; ◇,
NZBxNZW F1).
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myDCs from B6 and MRL/lpr mice have similar levels of TLR4 surface expression and no
difference in survival. myDCs within the CD11c+ splenocyte population were gated as
CD11chigh/CD11bint/high, and then analyzed for TLR4 expression (A). LPS-stimulated
BMDCs were stained with 7-AAD on day 4 (B). The thick black line represents B6 mice.
The thin gray line represents MRL/lpr mice. Histogram shows a representative plot from
three experiments.
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DCs from MRL/lpr mice show a decrease in synthesis and ability to sustain IL-6 mRNA
levels. Real-time PCR was performed on RNA isolated from LPS-stimulated BMDCs
untreated (A) or treated (B) with DRB at the indicated time points. The data from three
individual B6 (●) and six MRL/lpr (○) mice are plotted as %18S.
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DCs from MRL/lpr mice fail to activate NF-κB and AP-1. BMDCs were stimulated with
LPS (15 μg/ml) for the indicated times. Nuclear extracts were prepared, and NF-κB/DNA
binding (A) or AP-1/DNA binding (D) was assessed by EMSA. Nuclear extracts prepared
from unstimulated B6 BMDCs (lane 1) or from DCs stimulated 6 h with LPS (lanes 2–4)
were incubated with radiolabeled DNA probe (lanes 1–4), unlabeled competitive DNA (lane
3), or mutant DNA (lane 4), and NF-κB DNA binding was assessed by EMSA (B). NF-κB/
DNA complexes in the nuclear extracts from unstimulated B6 DCs (lane 1) or from DCs
stimulated 6 h with LPS (lane 2–5) were supershifted using p65 (lane 3), p50 (lane 4), or c-
Rel antiserum (lane 5) (C).
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TLR4-stimulated DCs from MRL/lpr mice are unable to sustain IκBα phosphorylation.
BMDCs (2 × 106) from B6 and MRL/lpr mice were stimulated with LPS (15 μg/ml) (A) or
poly(I:C) (50 μg/ml) (B) for the indicated time points. Phospho-IκBα, IκBα, and β-tubulin
(A) or β-actin (B) expression in whole cell lysates was determined by immunoblotting. Data
represent seven (A) and three (B) experiments.
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In addition to IL-6, other soluble factors regulate autoantibody secretion. Purified B cells (1
× 105) from 2-12H/Vκ8 mice were stimulated with LPS (30 μg/ml) in the absence (▲) or
presence of DC CM (25% of final volume) from B6 (●) or MRL/lpr (○) mice (A). DC CM
from individual MRL/lpr mice (○) was untreated or neutralized with anti-IL-6 Ab (50 μg/
ml) before coculture with B cells from 2-12H/Vκ8 mice (B). 5 × 104 purified B cells from
2-12H/Vκ8 and B6 mice were stimulated with LPS (30 μg/ml) in the absence (▲) or
presence of DC CM from B6 (●) or MRL/lpr (○) mice (C). Secreted IgMa/κ levels were
quantitated by ELISA from the day 4 culture supernatant. LPS-stimulated purified B cells
(100%) secreted 1–10 μg/ml IgMa/κ. Data represent 15 (A), 5 (B), and 4 (C) MRL/lpr mice.
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Table I
The frequencies of splenic myDCs and Mφs are not diminished in MRL/lpr micea
B6 MRL/lpr p Value
myDCs 1.02 ± 0.12 0.86 ± 0.07 0.658
lyDCs 0.13 ± 0.01 0.25 ± 0.03 0.001
b
pDCs 0.03 ± 0.01 0.10 ± 0.02 0.168
Mφs 1.68 ± 0.25 4.38 ± 0.96 0.002b
a
Splenic DC and Mφ subsets were analyzed based on CD11c, CD11b, B220, and GRI expression. The data depict the average percentage of total
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